Trevi Therapeutics Files 8-K: Material Agreement & Other Events
Ticker: TRVI · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1563880
Sentiment: neutral
Topics: material-agreement, filing-update
TL;DR
TREVI entered a material definitive agreement on 12/15/24. Other events and financials also filed.
AI Summary
On December 15, 2024, Trevi Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in New Haven, Connecticut.
Why It Matters
This 8-K filing indicates a significant development for Trevi Therapeutics, Inc. with the entry into a material definitive agreement, which could impact its business operations and future prospects.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of these events requires further investigation.
Key Numbers
- 001-38886 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-0834299 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- December 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- New Haven, Connecticut (location) — Address of Principal Executive Offices
- 06510 (zip_code) — Zip Code of Principal Executive Offices
- (203) 304-2499 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement entered into by Trevi Therapeutics, Inc. on December 15, 2024?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on December 15, 2024.
What are the 'Other Events' mentioned in the 8-K filing?
The filing lists 'Other Events' as an item information but does not provide specific details within the provided text.
Where are Trevi Therapeutics, Inc.'s principal executive offices located?
Trevi Therapeutics, Inc.'s principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
What is the SIC code for Trevi Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Trevi Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,135 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2024-12-16 17:20:59
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
- $4.00 — e price to investors in the Offering is $4.00 per share. The Company estimates that
- $46.7 million — from the Offering will be approximately $46.7 million after deducting underwriting discounts
Filing Documents
- d738809d8k.htm (8-K) — 33KB
- d738809dex11.htm (EX-1.1) — 193KB
- d738809dex51.htm (EX-5.1) — 10KB
- d738809dex991.htm (EX-99.1) — 8KB
- g738809dsp5.jpg (GRAPHIC) — 2KB
- g738809dsp6.jpg (GRAPHIC) — 2KB
- g738809dsp7.jpg (GRAPHIC) — 5KB
- 0001193125-24-279715.txt ( ) — 442KB
- trvi-20241215.xsd (EX-101.SCH) — 3KB
- trvi-20241215_lab.xml (EX-101.LAB) — 18KB
- trvi-20241215_pre.xml (EX-101.PRE) — 11KB
- d738809d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements uncertainties set forth in the "Risk Factors" section of the Company's Quarterly Report for the quarter ended September 30, 2024 filed with the SEC, and in subsequent filings with the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated December 15, 2024, by and among the Company and Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc. 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (contained in Exhibit 5.1 above) 99.1 Press Release, dated December 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: December 16, 2024 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer